TCFL5 Antibody

What is TCFL5 and why is it important in research?

TCFL5 (Transcription Factor-Like 5) is a testis-specific protein containing a basic helix-loop-helix domain that functions as both a DNA and RNA-binding protein. It plays a critical role in spermatogenesis and male fertility. Research has shown that TCFL5 transcriptionally and post-transcriptionally regulates genes essential for male germ cell development . Additionally, emerging evidence suggests TCFL5 may have roles in cancer biology, particularly colorectal cancer, with different isoforms showing distinct effects .

Which experimental applications are TCFL5 antibodies validated for?

TCFL5 antibodies have been validated for multiple experimental applications including:

• Western Blotting (WB) at dilutions of 1:500-1:2000

• Immunohistochemistry (IHC) at dilutions of 1:50-1:500

• Immunocytochemistry/Immunofluorescence (ICC/IF)

• ELISA at dilutions up to 1:20000

• Chromatin Immunoprecipitation (ChIP-seq)

• RNA Immunoprecipitation

What is the typical molecular weight observed for TCFL5 in Western blots?

The calculated molecular weight of TCFL5 is approximately 52 kDa (483 amino acids), but the observed molecular weight in Western blot experiments typically ranges between 52-60 kDa . This variation may be due to post-translational modifications or the detection of different isoforms. Some studies have also reported detecting a single, well-resolved TCFL5 band by Western blotting, contrary to previous observations that suggested multiple bands .

What are the optimal sample preparation methods for detecting TCFL5 in testicular tissue?

For optimal detection of TCFL5 in testicular tissue:

• Fixation: 4% paraformaldehyde fixation at 4°C is recommended

• Antigen retrieval: Heat-mediated antigen retrieval using citrate buffer (pH 6.0) or TE buffer (pH 9.0)

• Blocking: Use 5% non-fat milk for Western blotting applications

• Primary antibody incubation: Overnight at 4°C with dilutions between 1:100-1:500 for IHC and 1:500-1:2000 for WB

• Detection system: HRP-conjugated secondary antibodies (1:2000 dilution) and ECL reagent are effective for visualizing immunopositive bands

For nuclear proteins like TCFL5, ensure proper nuclear extraction protocols are followed when preparing samples for Western blotting or immunoprecipitation.

How should ChIP-seq experiments with TCFL5 antibodies be designed and optimized?

ChIP-seq experiments with TCFL5 antibodies require careful optimization:

• Sample source: TCFL5 is most abundant in primary spermatocytes. Using FACS-purified primary spermatocytes yields the clearest results .

• Cross-linking: Standard formaldehyde cross-linking (1%) for 10 minutes at room temperature.

• Sonication: Optimize to achieve DNA fragments of 200-500 bp.

• Antibody concentration: Verify antibody enrichment by Western blotting before proceeding with sequencing .

• Controls: Include input DNA and IgG controls.

• Data analysis: Model-based analysis has successfully identified TCFL5-binding sites, particularly at promoter regions near transcription start sites .

• Validation: Consider using CUT&RUN (Cleavage Under Targets & Release Using Nuclease) as a complementary approach to validate findings .

Studies have revealed that TCFL5 binding sites are often located at the transcription start sites of target genes, with a consensus binding motif identified as WANSWCGW (W = A or T; S = G or C) .

What is the expected expression pattern of TCFL5 during spermatogenesis?

TCFL5 shows a highly specific expression pattern during spermatogenesis:

• Cell type specificity: TCFL5 is primarily expressed in primary spermatocytes (pachytene and diplotene stages), with minimal or no expression in spermatogonia or Sertoli cells .

• Subcellular localization: TCFL5 localizes to the nuclei of primary spermatocytes .

• Temporal expression: TCFL5 is activated by A-MYB during meiosis, and subsequently, TCFL5 and A-MYB reinforce each other's expression through positive feedback .

• Expression levels: TCFL5 mRNA abundance peaks in primary spermatocytes compared to other testicular cell types .

Immunohistochemical staining should reveal nuclear localization in seminiferous tubules, specifically in cells at the pachytene stage of meiosis.

How do TCFL5 expression patterns differ between normal tissues and disease states?

TCFL5 expression shows distinct patterns between normal and disease states:

Normal tissues:

• High expression in testis, specifically in primary spermatocytes

• Detected in cerebral cortex neurons

• Little to no expression in normal liver and pancreas tissues

Disease states:

• Altered expression has been reported in colorectal cancer (CRC), where different isoforms appear to have opposing effects on tumor properties

• TCFL5 knockdown in diffuse large B-cell lymphoma (DLBCL) increased sensitivity to doxorubicin treatment via regulation of GPX4

When interpreting immunostaining results, consider both the intensity and subcellular localization of TCFL5, as changes in either may indicate pathological conditions.

How can TCFL5 antibodies be used to study its dual role as both a DNA and RNA-binding protein?

To investigate TCFL5's dual functionality:

• For DNA binding:

  • ChIP-seq to identify genomic binding sites (12,623 peak-associated genes have been identified)

  • DNA pull-down assays using biotinylated DNA containing TCFL5 consensus binding sequences

  • Electrophoretic mobility shift assays (EMSA) to assess direct binding to specific DNA sequences

• For RNA binding:

  • RNA Immunoprecipitation (RIP) using TCFL5 antibodies to pull down bound RNAs

  • Enhanced Crosslinking and Immunoprecipitation (eCLIP) to identify RNA targets with nucleotide resolution

  • TCFL5 antibodies can be used to investigate its interaction with known RNA-binding proteins like FXR1

• Integrated analysis:

  • Compare ChIP-seq and eCLIP-RNA datasets to identify genes regulated at both transcriptional and post-transcriptional levels

  • Analyze how TCFL5 coordinates these dual functions during spermatogenesis

This dual functionality makes TCFL5 a fascinating subject for studying integrated gene regulation mechanisms.

What methodological approaches can resolve contradictory reports about TCFL5 isoforms and bands detected in Western blots?

To address contradictory reports about TCFL5 isoforms:

• Isoform-specific antibodies: Design antibodies targeting unique regions of specific isoforms (e.g., TCFL5_E8 vs. CHA isoforms)

• Recombinant protein controls: Use purified recombinant proteins of each isoform as positive controls

• Validation in knockout models: Compare wildtype and knockout tissues to confirm specificity

• RNA expression analysis: Correlate protein bands with transcript expression using RT-PCR with isoform-specific primers

• Mass spectrometry: Identify proteins in each band to confirm identity and potential post-translational modifications

• Denaturing conditions: Optimize SDS-PAGE conditions to ensure complete denaturation and prevent alternative conformations

• Sample preparation: Use fresh samples and appropriate protease inhibitors to prevent degradation

Some studies have reported a single TCFL5 band by Western blotting , while others observe multiple bands. This may be due to tissue-specific expression of different isoforms, with colorectal cancer cells expressing four alternative transcripts of TCFL5 .

How can TCFL5 antibodies be used to investigate the A-MYB/TCFL5 regulatory architecture in pachytene piRNA production?

To study the A-MYB/TCFL5 regulatory network:

• Sequential ChIP (ChIP-reChIP): Use both A-MYB and TCFL5 antibodies sequentially to identify genomic regions bound by both proteins

• CUT&RUN in sorted cells: Perform CUT&RUN with both antibodies in FACS-purified primary spermatocytes to improve signal-to-noise ratio

• ChIP-seq time course: Trace the temporal order of binding during spermatogenesis

• Integrative analysis: Compare binding patterns of A-MYB and TCFL5 at pachytene piRNA gene promoters

• Genetic models: Use TCFL5 antibodies to examine A-MYB binding in TCFL5-deficient mice and vice versa

Research has shown that A-MYB and TCFL5 form an incoherent feedforward loop, where A-MYB initiates TCFL5 expression, and TCFL5 reinforces both its own expression and that of A-MYB . This regulatory circuit is particularly important for the expression of evolutionarily younger pachytene piRNA genes .

What are the common challenges in detecting TCFL5 in testicular samples and how can they be overcome?

Common challenges and solutions for TCFL5 detection:

How can researchers validate the specificity of TCFL5 antibodies in their experimental systems?

To validate TCFL5 antibody specificity:

• Genetic validation:

  • Compare staining patterns between wildtype and TCFL5 knockout/knockdown samples

  • Use heterozygous models (Tcfl5+/-) alongside complete knockouts

• Peptide competition assays:

  • Pre-incubate the antibody with the immunizing peptide

  • Observe elimination of specific signal

• Multiple antibody approach:

  • Compare results using antibodies raised against different epitopes

  • Consistent results across different antibodies support specificity

• Signal verification in positive/negative tissues:

  • Confirm strong signals in testis (positive control)

  • Verify absence of signal in tissues known not to express TCFL5 (e.g., liver, pancreas)

• Recombinant protein controls:

  • Use purified recombinant TCFL5 or TCFL5-overexpressing cell lines as positive controls

  • Include appropriate negative controls (e.g., empty vector transfected cells)

How can TCFL5 antibodies be utilized to explore its potential role in cancer biology?

To investigate TCFL5 in cancer:

• Isoform-specific studies:

  • Use isoform-specific antibodies to distinguish between TCFL5_E8 and CHA isoforms, which have opposing effects in colorectal cancer

  • Perform immunohistochemistry on cancer tissue microarrays to correlate isoform expression with clinical outcomes

• Mechanism exploration:

  • Study TCFL5 binding to promoters of pluripotency-related genes (SOX2, KLF4) in cancer stem cells

  • Investigate how TCFL5 regulates GPX4 in DLBCL to affect doxorubicin sensitivity

• Therapeutic applications:

  • Develop screening assays using TCFL5 antibodies to identify compounds that modulate its activity

  • Investigate whether TCFL5 can serve as a biomarker for treatment response

• Cancer stem cell research:

  • Use TCFL5 antibodies in flow cytometry to isolate and characterize cancer stem cells based on TCFL5 expression

  • Study the role of TCFL5 in spheroid formation and tumor initiation

What emerging techniques might enhance the utility of TCFL5 antibodies in studying male infertility mechanisms?

Emerging techniques for TCFL5 research in infertility:

• Single-cell approaches:

  • Single-cell CUT&RUN or CUT&Tag with TCFL5 antibodies to map protein-DNA interactions at the single-cell level

  • Single-cell proteomics to track TCFL5 expression throughout spermatogenesis

• Multiplexed imaging:

  • Cyclic immunofluorescence or imaging mass cytometry to simultaneously visualize TCFL5 and multiple interacting partners

  • Spatial transcriptomics combined with TCFL5 immunostaining to correlate protein localization with transcriptional activity

• Liquid biopsy applications:

  • Develop assays to detect TCFL5 or its regulated targets in seminal fluid as potential biomarkers for spermatogenic failure

  • Correlate TCFL5 expression with sperm parameters in infertility patients

• Therapeutic approaches:

  • Use TCFL5 antibodies to screen for compounds that might restore proper TCFL5 expression in cases of dysregulation

  • Investigate whether TCFL5 activity could be a target for male contraceptive development